ITeos Therapeutics Inc (NAS:ITOS)
$ 18.03 -0.06 (-0.33%) Market Cap: 651.30 Mil Enterprise Value: 210.14 Mil PE Ratio: 0 PB Ratio: 1.20 GF Score: 40/100

Iteos Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 02:10PM GMT
Release Date Price: $32.54
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My Name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team.

Our next presenting company is iTeos. (Operator Instructions)

With that, I will turn it over to Michel. Michel?

Michel Detheux
iTeos Therapeutics, Inc. - President, CEO & Director

Thank you very much for the introduction, Anupam. I'm very pleased to present iTeos at this 2021 JPMorgan conference. iTeos has built an expertise in immuno-oncology by developing novel therapies focused on well-established mechanisms of immunosuppression with differentiated strategies.

I'm going to describe today our pipeline, the progress made in 2020 and the multiple opportunities and inflection points in the near future. On Slide 2, the presentation contains forward-looking statements that could impact our risk factor. This risk factor can be found in our public filings

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot